Back to Awarded Treatment Trials
Awarded Trial: 02T-192
Secondary Drug Intervention
Duration of Study Period for Each Subject
MADRS, YMRS, CGI-BP, GAF-C, PANSS positive
In patients with bipolar depression that did not respond to standard mood stabilizer treatment, aripiprazole was associated with a significant improvement in depression scores. However, only 45% of patients completed the 8-week trial. Forty-two percent of patients were responders (>50% reduction is MADRS scores) and 35% of patients achieved remission (MADRS <12). Akathisia was a common side effect.
McElroy S.L., Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE Jr. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord. 2007 Aug;101(1-3):275-81.
Psychiatric Professional Services, Inc.
University of Cincinnati College of Medicine
231 Albert Sabin Way
City or Town
State or Province
Zip or Postal Code